• Explore /
  • Poster
  • / Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.

Intensive chemotherapy (IC) versus hypomethylating agents (HMA) for the treatment of younger patients with myelodysplastic syndrome (MDS) and elevated bone marrow blasts.

Abstract Poster

Authors

null

Paolo Strati

The University of Texas MD Anderson Cancer Center, Houston, TX

Paolo Strati , Guillermo Garcia-Manero , Tapan M. Kadia , Gautam Borthakur , Marina Konopleva , Naval Guastad Daver , Courtney Denton Dinardo , Nicholas James Short , Musa Yilmaz , Kiran Naqvi , Sherry Pierce , Jorge E. Cortes , Hagop M. Kantarjian , Farhad Ravandi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myelodysplastic Syndromes (MDS)

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7064)

DOI

10.1200/JCO.2018.36.15_suppl.7064

Abstract #

7064

Poster Bd #

124

Abstract Disclosures

Similar Posters

First Author: Amy Elizabeth Dezern

First Author: Amer Methqal Zeidan

First Author: Eric Huselton

First Author: Chun Yew Fong